Novast Holdings completes RMB1b private equity transaction led by Legend Capital

Novast Holdings announced the completion of nearly 1 billion yuan in private equity transactions. This transaction was jointly invested by Legend Capital, Shiyu Capital, China C&D, Service Trade Fund, Highlight Capital and Highsino.

Novast Holdings announced the completion of nearly 1 billion yuan in private equity transactions. This transaction was jointly invested by Legend Capital, Shiyu Capital, China C&D, Service Trade Fund, Highlight Capital and Highsino.

Novast Holdings was founded by President Zhang Guohua and its technical management team in Nantong, Jiangsu in 2005. The team members are composed of scientists and engineers from China, the United States, Canada and India, who have extensive management and technical experience in the international pharmaceutical industry.

Since its inception, the company has been focusing on the research and product development of drug delivery systems and sustained-release preparations. During the team members’ careers, they have successfully developed more than 180 new drugs and generic drug preparations for the global pharmaceutical industry.

As of April 2020, Novast Holdings has a total of 40 pharmaceutical preparations approved by the FDA, including more than 30 hormone products and 9 sustained-release products, several of which have a leading market share in the United States.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/12/novast-holdings-completes-rmb1b-private-equity-transaction-led-by-legend-capital/.

Leave a Reply

Please Login to Comment